ASCO® 2023 Insights: "Post Hoc Analysis of Patients With Nonviral Etiology From REFLECT Trial - Efficacy of Lenvatinib vs. Sorafenib in the 1L Treatment of Patients With Unresectable HCC"

70 views
July 17, 2023
Comments 0
Login to view comments. Click here to Login